Fresenius completes mAbxience deal while Fresenius stock trades 16.37 percent below its high

Published on 10/06/2026 at 12:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The deal includes EUR 50.00 million tied to site approvals. Fresenius stock costs EUR 44.29 on October 6, 2026 after EUR 44.11, plus 0.41 percent.

Fresenius SE – Fotorealistisch: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht — Fresenius SE & Co. KGaA (ISIN DE0005785604) ist ein internationaler Gesundheitskonzern mit Sitz in Bad Homburg. Das Unternehmen betreibt Krankenhäuser und entwickelt Arzneimittel und Infusionslösungen. Dieses Bild zeigt: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht, Illustration mit AI erstellt.

Fresenius stock (ISIN DE000FRE5EN2) was at EUR 44.29 at Lang & Schwarz on October 6, 2026 at 12:16 p.m. CEST, 16.37 percent below its 52-week high of EUR 52.96. Fresenius completed its mAbxience deal on September 30, 2026, paying up to EUR 750.00 million for the remaining 45 percent, according to Fresenius on October 1, 2026.

Full ownership strengthens biosimilars

The transaction gives Fresenius full ownership of mAbxience, which now sits entirely within Fresenius Kabi's Biopharma business. The payment includes a contingent EUR 50.00 million component tied to site approvals, while Fresenius said no new financing was required.

mAbxience generated more than EUR 320.00 million in revenue in fiscal year 2025 and operates three manufacturing facilities in Spain and Latin America. Its platform has four products on the market and eight candidates in development, giving Fresenius control of research, manufacturing, regulatory work and commercialization.

Second-quarter figures show operating progress

Fresenius reported Q2 2026 group revenue of EUR 5.864 billion, up 6.00 percent from EUR 5.571 billion in Q2 2025. Group EBIT before special items reached EUR 719.00 million, 10.00 percent above EUR 654.00 million a year earlier, while core net income rose 14.00 percent to EUR 470.00 million, according to Fresenius.

The contrast matters for the stock: the acquisition adds strategic control in biopharmaceuticals, while the latest operating figures show that the investment case also rests on improved earnings quality. UBS kept a Buy rating and a EUR 56.00 price target on September 17, 2026, according to FinanzNachrichten.

Stock remains below its yearly high

At EUR 44.29, the Lang & Schwarz quote stood EUR 8.67 below the 52-week high and above the 52-week low of EUR 35.11 on October 6, 2026. The prior close at Lang & Schwarz was EUR 44.11, making the daily change plus 0.41 percent.

The further course of trading is shown by the continuously updated real-time quote of Fresenius stock.